Attendee search 

以尖端生命科学技术转化为核心，专注于ReproCore超微因子系列生物制品的研发、生产、销售、服务为主营业务，涉及医学康养、医学美容、健康调理、精准医疗等领域，以严谨的科学态度、严格的技术标准、完备的质量保障、一流的产品服务，致力于为广大消费者，特别是社会高端人群打造全生命周期的个性化健康定制咨询、产品、服务、管理于一体的健康生态平台。

Located in Jinan, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. It focuses on developing, manufacturing and marketing of generic drugs and active pharmaceutical ingredients in the therapeutic areas of Oncology, Cerebrovascular & Cardiovascular, Infections, Psychological&Neurological System, Respiratory System, Ophthalmological Diseases, etc. Qilu has more than 8000 employees, 70% of which have the college degree or above.

Qilu pharmaceutical has always been sticking to the innovative development strategy. Guided by the market demand and the product innovation, Qilu has established extensive cooperation with domestic and foreign partners on a series of R&D projects. Qilu pays high attention to the introduction and cultivation of talents and has built a highly qualified R&D team with professional and efficient R&D capabilities, More than 100 national new drugs have been successfully developed, which constitutes the reasonable production line for the future development of Qilu. A number of technological achievements have obtained the national and provincial scientific & technological progress awards and created good social benefit.

Qilu Pharmaceutical has eight manufacturing sites covering an area of more than 2800,000 ㎡for finished dosage forms, chemical synthesis, genetic-engineering, fermentation, etc. The modern workshops are located in the manufacturing sites where the automatic production lines, key equipments and analytical instruments are imported from the leading suppliers all over the world. Now Qilu Pharmaceutical has been one of the leading global suppliers of Antibiotic APIs and Oncology APIs with huge capacity and good quality.

Qilu pharmaceutical has always been committing itself to providing the high-quality products to the patients and the society. Thanks to the integrated and stringent system of quality control and quality assurance, the company has been the leader of cGMP implementation in China. Its non-sterile APIs (fermentation and chemical synthesis), sterile APIs and comprehensive finished dosages have been respectively approved by USFDA, European Directorate for the Quality of Medicines (EDQM), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, Medicines Control Council (MCC) of South Africa, and some other national competent authorities.

Qilu Pharmaceutical has an integrated product structure and value chain with over 160 launched products. The company has established a comprehensive domestic and overseas sales network. The global presence has covered North America, Europe, CIS countries, South America, Asia, South Africa and Middle East. The valuable brand of the company has been well built with the quality products and good services.

Big Pharma

华润集团一级利润中心，聚焦生命科学领域投资与合作

Genetron

WuXi Apptec provides a broad portfolio of R&D and manufacturing service that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients.

EpimAb's innovative FIT-Ig technology offers a game-changing approach to a broad variety of bi-specific antibodies. The technology provides access to stable bi-specifics by applying conventional molecular biology techniques. FIT-Ig molecules demonstrate properties similar to therapeutically active antibodies. They are actually manufactured like antibodies using standard processes at yields and purities similar to antibodies, e.g. EMB01, our first candidate was developed from cell line to IND submission date in 15 months, produced 3,5 g/l in a standard cell line and was easily purified with 70% recovery. Further candidates are manufactured with even higher yields.

EpimAb is developing a portfolio of bispecific antibodies for the treatment of different oncology indications. The first asset, EMB01, a first in class dual c-Met and EGFR inhibitor, is currently being investigated in a PhI/II study for treatment of solid tumors.

EMB02 (IND filing Q2/2020) and EMB04 are immune oncology biologics and EMB06 (IND filing Q4/2020) is a bispecific T-cell engager. In addition EMB08 (IND filing 2021) is a bispecific fusion protein.

EpimAb is committed to diversifying its portfolio of FIT-Igs in order to further validate the flexibility and robustness of the format and its platform. The broad applicability of this technology enables EpimAb to pursue two concurrent strategies for commercializing the technology:

•      Grant licenses to other pharmaceutical companies to combine two antibodies into a FIT-Ig themselves. Through this initiative EpimAb intends to catalyze the broad use of FIT-Igs for the benefit of scientists, the medical community and eventually patients; and

•      Create and develop proprietary FIT-Igs enabling EpimAb to grow and develop a discovery and development organization, generate FIT-Igs of great value to patients and medical experts and also improve its technological approach to bi-specific antibodies for the benefit of the scientific community.

CRO based in Shanghai

Mabgen Biotech is a Hengrui Group company, focusing on the CMC part of biologics development.

We are a clinical stage biopharma company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders